Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$155.44 USD

155.44
1,851,978

+1.95 (1.27%)

Updated Nov 5, 2024 02:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Is Illumina (ILMN) a Great Growth Stock?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Illumina (ILMN).

The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp

by Zacks Equity Research

The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp

Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Nalak Das headshot

Wall Street Likely to Sustain Post-Midterm Rally: 5 Picks

by Nalak Das

Investors' optimism has been revived on risky assets like equities with a divided U.S. Congress.

Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y

by Zacks Equity Research

Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.

Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences

by Zacks Equity Research

Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.

Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Illumina (ILMN) closed at $322.73 in the latest trading session, marking a -0.43% move from the prior day.

Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings

by Zacks Equity Research

Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings

Sanghamitra Saha headshot

Go Beyond Earnings Growth, Bet on Beat With 5 Stocks

by Sanghamitra Saha

These top-ranked stocks are likely to beat on bottom line in their next releases.

Illumina (ILMN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Illumina (ILMN) closed at $292.25, marking a -0.97% move from the previous day.

The Zacks Analyst Blog Highlights: Procter & Gamble, Philip Morris, Honeywell, Lockheed and Illumina

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Procter & Gamble, Philip Morris, Honeywell, Lockheed and Illumina

Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3

by Zacks Equity Research

Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.

Mark Vickery headshot

Top Analyst Reports for Procter & Gamble, Philip Morris & Honeywell

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Philip Morris (PM) and Honeywell (HON).

Illumina (ILMN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 21.60% and 3.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Why Illumina (ILMN) Might Surprise This Earnings Season

by Zacks Equity Research

Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AMGN or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMGN vs. ILMN: Which Stock Is the Better Value Option?

Pacific Biosciences Introduces Enhancements to Sequel System

by Zacks Equity Research

The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.

    Illumina (ILMN) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    Illumina (ILMN) closed the most recent trading day at $328.96, moving +0.73% from the previous trading session.

    Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?

    by Zacks Equity Research

    Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.

    Illumina (ILMN) Q3 Earnings Preview: What's in the Cards?

    by Zacks Equity Research

    Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Illumina (ILMN) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    Illumina (ILMN) closed the most recent trading day at $307.45, moving +0.88% from the previous trading session.

    Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

    by Zacks Equity Research

    Sector ETF report for PBE

    Why Illumina (ILMN) Could Beat Earnings Estimates Again

    by Zacks Equity Research

    Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

      Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce

      by Zacks Equity Research

      Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).